755.02 USD
+13.57 (+1.83%)
At close: Feb 2, 2026
755.02 USD
0 (0%)
After Hours: 2/2/2026, 8:37:15 PM
We assign a fundamental rating of 6 out of 10 to REGN. REGN was compared to 524 industry peers in the Biotechnology industry. REGN gets an excellent profitability rating and is at the same time showing great financial health properties. REGN has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
- In the past year REGN was profitable.
- In the past year REGN had a positive cash flow from operations.
- In the past 5 years REGN has always been profitable.
- REGN had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
- REGN's Return On Assets of 11.40% is amongst the best of the industry. REGN outperforms 94.27% of its industry peers.
- The Return On Equity of REGN (14.79%) is better than 94.66% of its industry peers.
- Looking at the Return On Invested Capital, with a value of 9.82%, REGN belongs to the top of the industry, outperforming 94.85% of the companies in the same industry.
- REGN had an Average Return On Invested Capital over the past 3 years of 11.32%. This is significantly below the industry average of 18.09%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.4% | ||
| ROE | 14.79% | ||
| ROIC | 9.82% |
ROA(3y)11.58%
ROA(5y)16.27%
ROE(3y)14.89%
ROE(5y)21.37%
ROIC(3y)11.32%
ROIC(5y)18.04%
1.3 Margins
- The Profit Margin of REGN (32.13%) is better than 96.56% of its industry peers.
- REGN's Profit Margin has declined in the last couple of years.
- Looking at the Operating Margin, with a value of 27.61%, REGN belongs to the top of the industry, outperforming 96.56% of the companies in the same industry.
- REGN's Operating Margin has declined in the last couple of years.
- REGN has a Gross Margin of 86.28%. This is amongst the best in the industry. REGN outperforms 88.93% of its industry peers.
- In the last couple of years the Gross Margin of REGN has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 27.61% | ||
| PM (TTM) | 32.13% | ||
| GM | 86.28% |
OM growth 3Y-15.55%
OM growth 5Y-9.14%
PM growth 3Y-4.13%
PM growth 5Y-5.35%
GM growth 3Y-1.5%
GM growth 5Y-0.34%
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), REGN is creating some value.
- REGN has less shares outstanding than it did 1 year ago.
- Compared to 5 years ago, REGN has less shares outstanding
- Compared to 1 year ago, REGN has an improved debt to assets ratio.
2.2 Solvency
- An Altman-Z score of 7.38 indicates that REGN is not in any danger for bankruptcy at the moment.
- With a decent Altman-Z score value of 7.38, REGN is doing good in the industry, outperforming 78.44% of the companies in the same industry.
- REGN has a debt to FCF ratio of 0.70. This is a very positive value and a sign of high solvency as it would only need 0.70 years to pay back of all of its debts.
- REGN's Debt to FCF ratio of 0.70 is amongst the best of the industry. REGN outperforms 94.66% of its industry peers.
- REGN has a Debt/Equity ratio of 0.09. This is a healthy value indicating a solid balance between debt and equity.
- REGN has a worse Debt to Equity ratio (0.09) than 61.64% of its industry peers.
- Even though the debt/equity ratio score it not favorable for REGN, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 0.7 | ||
| Altman-Z | 7.38 |
ROIC/WACC1.13
WACC8.67%
2.3 Liquidity
- A Current Ratio of 4.06 indicates that REGN has no problem at all paying its short term obligations.
- REGN's Current ratio of 4.06 is in line compared to the rest of the industry. REGN outperforms 48.85% of its industry peers.
- REGN has a Quick Ratio of 3.51. This indicates that REGN is financially healthy and has no problem in meeting its short term obligations.
- REGN's Quick ratio of 3.51 is in line compared to the rest of the industry. REGN outperforms 44.08% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.06 | ||
| Quick Ratio | 3.51 |
3. Growth
3.1 Past
- REGN shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -2.76%.
- The Earnings Per Share has been growing slightly by 6.99% on average over the past years.
- REGN shows a small growth in Revenue. In the last year, the Revenue has grown by 0.99%.
- The Revenue has been growing by 11.04% on average over the past years. This is quite good.
EPS 1Y (TTM)-2.76%
EPS 3Y1.53%
EPS 5Y6.99%
EPS Q2Q%-5.22%
Revenue 1Y (TTM)0.99%
Revenue growth 3Y5.62%
Revenue growth 5Y11.04%
Sales Q2Q%2.51%
3.2 Future
- Based on estimates for the next years, REGN will show a quite strong growth in Earnings Per Share. The EPS will grow by 10.05% on average per year.
- REGN is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.12% yearly.
EPS Next Y4.14%
EPS Next 2Y12.18%
EPS Next 3Y8.22%
EPS Next 5Y10.05%
Revenue Next Year6.89%
Revenue Next 2Y8.55%
Revenue Next 3Y7.27%
Revenue Next 5Y7.12%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
- REGN is valuated rather expensively with a Price/Earnings ratio of 17.01.
- Based on the Price/Earnings ratio, REGN is valued cheaper than 95.61% of the companies in the same industry.
- REGN is valuated rather cheaply when we compare the Price/Earnings ratio to 28.41, which is the current average of the S&P500 Index.
- The Price/Forward Earnings ratio is 16.34, which indicates a correct valuation of REGN.
- Compared to the rest of the industry, the Price/Forward Earnings ratio of REGN indicates a rather cheap valuation: REGN is cheaper than 95.04% of the companies listed in the same industry.
- Compared to an average S&P500 Price/Forward Earnings ratio of 25.64, REGN is valued a bit cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 17.01 | ||
| Fwd PE | 16.34 |
4.2 Price Multiples
- Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of REGN indicates a rather cheap valuation: REGN is cheaper than 94.85% of the companies listed in the same industry.
- Based on the Price/Free Cash Flow ratio, REGN is valued cheaper than 95.23% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 20.45 | ||
| EV/EBITDA | 14.86 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates REGN does not grow enough to justify the current Price/Earnings ratio.
- The decent profitability rating of REGN may justify a higher PE ratio.
PEG (NY)4.11
PEG (5Y)2.43
EPS Next 2Y12.18%
EPS Next 3Y8.22%
5. Dividend
5.1 Amount
- With a yearly dividend of 0.51%, REGN is not a good candidate for dividend investing.
- Compared to an average industry Dividend Yield of 1.12, REGN pays a better dividend. On top of this REGN pays more dividend than 98.28% of the companies listed in the same industry.
- With a Dividend Yield of 0.51, REGN pays less dividend than the S&P500 average, which is at 1.83.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.51% |
5.2 History
- REGN is new to the dividend game and has less than 3 years of track record.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
DPN/A
EPS Next 2Y12.18%
EPS Next 3Y8.22%
REGENERON PHARMACEUTICALS / REGN FAQ
Can you provide the ChartMill fundamental rating for REGENERON PHARMACEUTICALS?
ChartMill assigns a fundamental rating of 6 / 10 to REGN.
What is the valuation status of REGENERON PHARMACEUTICALS (REGN) stock?
ChartMill assigns a valuation rating of 6 / 10 to REGENERON PHARMACEUTICALS (REGN). This can be considered as Fairly Valued.
Can you provide the profitability details for REGENERON PHARMACEUTICALS?
REGENERON PHARMACEUTICALS (REGN) has a profitability rating of 7 / 10.
What is the financial health of REGENERON PHARMACEUTICALS (REGN) stock?
The financial health rating of REGENERON PHARMACEUTICALS (REGN) is 8 / 10.